Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.72 |
| ▸ | AXL | P30530 | 9/20 | 0.72 |
| ▸ | KDR | P35968 | 7/20 | 0.72 |
| ▸ | MERTK | Q12866 | 6/20 | 0.66 |
| ▸ | FLT3 | P36888 | 4/20 | 0.65 |
| ▸ | RET | P07949 | 3/20 | 0.65 |
| ▸ | KIT | P10721 | 3/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.64 |
| ▸ | FLT1 | P17948 | 3/20 | 0.64 |
| ▸ | AURKA | O14965 | 2/20 | 0.64 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.64 |
| ▸ | ABL1 | P00519 | 2/20 | 0.64 |
| ▸ | EGFR | P00533 | 2/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.64 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.64 |
| ▸ | LCK | P06239 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL469291 | 0.89 | MET (0.83) | METAXLKDRMERTKFLT3 | |
| Exelixis SCHEMBL371899 | 0.85 | MET (1.00) | METAXLKDRMERTKFLT3 | |
| Exelixis SCHEMBL29693473 | 0.85 | MET (1.00) | METAXLKDRMERTKFLT3 | |
| SCHEMBL469347 | 0.84 | MET (0.84) | METAXLKDRMERTKFLT3 | |
| SCHEMBL20096226 | 0.84 | MET (0.87) | METAXLKDRMERTKFLT3 | |
| SCHEMBL469346 | 0.83 | MET (0.71) | METAXLKDRMERTKFLT3 | |
| SCHEMBL21847915 | 0.83 | MET (0.81) | METAXLKDRMERTKFLT3 | |
| SCHEMBL29693523 | 0.83 | MET (0.83) | METAXLKDRMERTKFLT3 | |
| SCHEMBL29693522 | 0.83 | MET (0.83) | METAXLKDRMERTKFLT3 | |
| SCHEMBL4401192 | 0.83 | MET (0.83) | METAXLKDRMERTKFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621904-B1 | COMPOUNDS AS C-MET KINASE INHIBITORS | ADVENCHEN LABORATORIES LLC (US) | 2020-04-22 | — | — | EP | claimed |
| US-8664244-B2 | Compounds as c-Met kinase inhibitors | Advenchen Pharmaceuticals, LLC (US) | 2014-03-04 | — | — | US | claimed |
| US-20120123126-A1 | Compounds As c-Met Kinase Inhibitors | CHEN GUOQING PAUL (US) | 2012-05-17 | — | — | US | claimed |
| EP-2621904-B1 | COMPOUNDS AS C-MET KINASE INHIBITORS | ADVENCHEN LABORATORIES LLC (US) | 2020-04-22 | — | — | EP | disclosed |
| US-8664244-B2 | Compounds as c-Met kinase inhibitors | Advenchen Pharmaceuticals, LLC (US) | 2014-03-04 | — | — | US | disclosed |
| EP-2621904-A2 | COMPOUNDS AS C-MET KINASE INHIBITORS | Advenchen Laboratories, LLC (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20120123126-A1 | Compounds As c-Met Kinase Inhibitors | CHEN GUOQING PAUL (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2012034055-A2 | COMPOUNDS AS C-MET KINASE INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123126-A1 | Compounds As c-Met Kinase Inhibitors | MET, MERTK, HGF | MET 1/4885AXL 75/4885KDR 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.